Compare AROW & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AROW | ANL |
|---|---|---|
| Founded | 1851 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.9M | 703.3M |
| IPO Year | 1995 | 2022 |
| Metric | AROW | ANL |
|---|---|---|
| Price | $37.37 | $16.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $28.00 | $20.00 |
| AVG Volume (30 Days) | 94.8K | ★ 551.4K |
| Earning Date | 04-30-2026 | 04-10-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 49.72 | N/A |
| EPS | ★ 2.65 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.36 | $36.02 |
| Revenue Next Year | $18.26 | N/A |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.36 | $0.88 |
| 52 Week High | $38.09 | $16.97 |
| Indicator | AROW | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 77.65 | 74.22 |
| Support Level | $31.14 | $1.36 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.82 | 2.40 |
| MACD | 0.26 | 0.75 |
| Stochastic Oscillator | 85.08 | 97.83 |
Arrow Financial Corp is a holding company. It provides various advisory and administrative services and coordinates the general policies and operations of the banks. It provides financial products, including online and mobile banking, mortgages, commercial loans, investments, and others. The company also provides lending services, including commercial and industrial lending to small and mid-sized companies; mortgage lending for residential and commercial properties; and consumer installment and home equity financing. The key source of the company's revenue is interest income, fees, commission earned through its subsidiaries.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.